Indication of laboratory parameters for kidney diseases at King Fahad Medical City, Riyadh, Saudi Arabia

Authors

  • Yousef Sultan Alobaisi King Fahad Medical City, Pathology and Clinical Laboratory Medicine Administration, Riyadh, 11525, Saudi Arabia
  • Firoz Anwar King Abdulaziz University, Department of Biochemistry, Faculty of Science, Jeddah, Saudi Arabia
  • Khaled Dabour Tanta University, Department of Entomology, Faculty of Science, Tanta, 31527, Egypt
  • Khalid Almatham King Fahad Medical City, Department of Nephrology, Riyadh, 11525, Saudi Arabia
  • Sultan Alshahrani King Fahad Medical City, Pathology and Clinical Laboratory Medicine Administration, Riyadh, 11525, Saudi Arabia
  • Khalid A. Alzahrani King Fahad Medical City, Department of Electronic Medical Records (EMR), Riyadh, Saudi Arabia
  • Yasir Awad Ahmed King Fahad Medical City, Pathology and Clinical Laboratory Medicine Administration, Riyadh, 11525, Saudi Arabia
  • Maher Mohammed Alobaysi King Fahad Medical City, Simulation Development Department, Academic and Training Affairs, Riyadh, 11525, Saudi Arabia

DOI:

https://doi.org/10.54536/ajmsi.v4i2.5340

Keywords:

Acute Kidney Failure (AKF), Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD), Laboratory Biomarkers

Abstract

End-stage renal disease (ESRD), chronic kidney disease (CKD), and acute kidney failure (AKF) are serious global health issues that contribute to high sickness and death rates. This King Fahad Medical City study investigated the importance of reliable biomarker monitoring and early treatment to enhance patient outcomes. 220 people had their serum levels of albumin, C-reactive protein (CRP), urea, creatinine, salt and phosphate assessed. Creatinine (χ² = 60.73, p < 0.001), urea (χ² = 48.66, p < 0.001), phosphate (χ² = 19.20, p = 0.004), sodium (χ² = 14.10, p = 0.029) and body weight (χ² = 13.24, p = 0.039) showed significant differences across diagnostic groups, according to the Kruskal-Wallis test. Significant activity was indicated by the highest CRP values (103.9 mg/L; 95% CI: 83.9–123.9 mg/L) in AKF patients, whereas the highest average creatinine levels (428.6 µmol/L; 95% CI: 330.0–527.2 µmol/L) were seen in ESRD patients. The above results show that every disease has an unique biomarker signature. Also a gender study revealed that, on average, male patients weighed 7.29 kg heavier than female patients (t = 2.739, p = 0.007). The study shows that kidney-related illnesses may be effectively treated with biomarker-based diagnostics.Important biomarkers for CKD, ESRD and AKF detection include creatinine, urea, CRP and sodium. This highlights how helpful these indicators are for supporting timely diagnosis, improving clinical intervention techniques and directing customized treatment plans.

Downloads

Download data is not yet available.

References

Al-Sayyari, A. A., & Shaheen, F. A. (2011). End stage chronic kidney disease in Saudi Arabia. A rapidly changing scene Saudi Med J, 32, 339-346.

Bektay, M. Y., Buker Cakir, A., Gursu, M., Kazancioglu, R., & Izzettin, F. V. (2024). An Assessment of Different Decision Support Software from the Perspective of Potential Drug–Drug Interactions in Patients with Chronic Kidney Diseases. Pharmaceuticals, 17(5), 562.

Brookes, E. M., & Power, D. A. (2022). Elevated serum urea-to-creatinine ratio is associated with adverse inpatient clinical outcomes in non-end stage chronic kidney disease. Scientific reports, 12(1), 20827.

Cappola, A. R., Auchus, R. J., El-Hajj Fuleihan, G., Handelsman, D. J., Kalyani, R. R., McClung, M., Stuenkel, C. A., Thorner, M. O., & Verbalis, J. G. (2023). Hormones and aging: an endocrine society scientific statement. The Journal of Clinical Endocrinology & Metabolism, 108(8), 1835-1874.

Chen, T. K., Sperati, C. J., Thavarajah, S., & Grams, M. E. (2021). Reducing kidney function decline in patients with CKD: core curriculum 2021. American Journal of Kidney Diseases, 77(6), 969-983.

Duff, S., Irwin, R., Cote, J. M., Redahan, L., McMahon, B. A., Marsh, B., Nichol, A., Holden, S., Doran, P., & Murray, P. T. (2022). Urinary biomarkers predict progression and adverse outcomes of acute kidney injury in critical illness. Nephrology Dialysis Transplantation, 37(9), 1668-1678.

Filipska, A., Bohdan, B., Wieczorek, P. P., & Hudz, N. (2021). Chronic kidney disease and dialysis therapy: incidence and prevalence in the world. Pharmacia, 68, 463-470.

Gremese, E., Bruno, D., Varriano, V., Perniola, S., Petricca, L., & Ferraccioli, G. (2023). Serum albumin levels: a biomarker to be repurposed in different disease settings in clinical practice. Journal of Clinical Medicine, 12(18), 6017.

Jiang, J., Tan, C., Zhou, W., Peng, W., Zhou, X., Du, J., Wang, H., Mo, L., Liu, X., & Chen, L. (2021). Plasma C-reactive protein level and outcome of acute ischemic stroke patients treated by intravenous thrombolysis: a systematic review and meta-analysis. European neurology, 84(3), 145-150.

Jiang, Z., Wang, Y., Zhao, X., Cui, H., Han, M., Ren, X., Gang, X., & Wang, G. (2023). Obesity and chronic kidney disease. American Journal of Physiology-Endocrinology and Metabolism.

Kovesdy, C. P. (2022). Epidemiology of chronic kidney disease: an update 2022. Kidney international supplements, 12(1), 7-11.

Kulvichit, W., Kellum, J. A., & Srisawat, N. (2021). Biomarkers in acute kidney injury. Critical care clinics, 37(2), 385-398.

Kuo, I. Y., & Chapman, A. B. (2020). Polycystins, ADPKD, and cardiovascular disease. Kidney international reports, 5(4), 396-406.

Li, J., Chen, J., Lan, H.-y., & Tang, Y. (2023). Role of C-reactive protein in kidney diseases. Kidney Diseases, 9(2), 73-81.

Major, R. W., Cheng, M. R., Grant, R. A., Shantikumar, S., Xu, G., Oozeerally, I., Brunskill, N. J., & Gray, L. J. (2018). Cardiovascular disease risk factors in chronic kidney disease: A systematic review and meta-analysis. PloS one, 13(3), e0192895.

McMahon, B. A., Galligan, M., Redahan, L., Martin, T., Meaney, E., Cotter, E. J., Murphy, N., Hannon, C., Doran, P., & Marsh, B. (2019). Biomarker predictors of adverse acute kidney injury outcomes in critically ill patients: the Dublin Acute Biomarker Group Evaluation Study. American Journal of Nephrology, 50(1), 19-28.

Mizdrak, M., Kumrić, M., Kurir, T. T., & Božić, J. (2022). Emerging biomarkers for early detection of chronic kidney disease. Journal of personalized medicine, 12(4), 548.

Mori, K., Furuhashi, M., Tanaka, M., Higashiura, Y., Koyama, M., Hanawa, N., & Ohnishi, H. (2022). Serum uric acid level is associated with an increase in systolic blood pressure over time in female subjects: Linear mixed-effects model analyses. Hypertension Research, 45(2), 344-353.

Okoro, R. N., & Farate, V. T. (2019). The use of nephrotoxic drugs in patients with chronic kidney disease. International Journal of Clinical Pharmacy, 41, 767-775.

Schrauben, S. J., Apple, B. J., & Chang, A. R. (2022). Modifiable lifestyle behaviors and CKD progression: a narrative review. Kidney360, 3(4), 752-778.

Sri-Ganeshan, M., Walker, K. P., Lines, T. J., Neal-Williams, T. J., Sheffield, E. R., Yeoh, M. J., & Taylor, D. M. (2022). Evaluation of a calcium, magnesium and phosphate clinical ordering tool in the emergency department. The American Journal of Emergency Medicine, 53, 163-167.

Stenvinkel, P., Chertow, G. M., Devarajan, P., Levin, A., Andreoli, S. P., Bangalore, S., & Warady, B. A. (2021). Chronic inflammation in chronic kidney disease progression: role of Nrf2. Kidney international reports, 6(7), 1775-1787.

Tang, Y., Mak, S. K., Xu, A. P., & Lan, H. Y. (2018). Role of C-reactive protein in the pathogenesis of acute kidney injury. Nephrology, 23, 50-52.

Valson, A. T., Sahay, M., Prasad, N., Agarwal, S. K., Varughese, S., & Gang, S. (2020). KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention and Prevention of Chronic Kidney Disease–Mineral and Bone Disorder (CKDMBD): Indian Commentary. Indian Journal of Nephrology, 30(4), 221-233.

Vásquez-Vera, C., Fernández, A., & Borrell, C. (2022). Gender-based inequalities in the effects of housing on health: a critical review. SSM-Population Health, 17, 101068.

Wang, A. Y.-M., Akizawa, T., Bavanandan, S., Hamano, T., Liew, A., Lu, K.-C., Lumlertgul, D., Oh, K.-H., Zhao, M.-H., & Fung, S. K.-S. (2019). 2017 kidney disease: improving global outcomes (KDIGO) chronic kidney disease–mineral and bone disorder (CKD-MBD) guideline update implementation: Asia summit conference report. Kidney international reports, 4(11), 1523-1537.

Wang, W., Xie, Y., Huang, X., Zhou, Y., & Luo, L. (2022). The value of N-terminal pro-brain natriuretic peptide and hs-CRP in predicting acute kidney injury after acute myocardial infarction. American Journal of Translational Research, 14(8), 5501.

Webster, A. C., Nagler, E. V., Morton, R. L., & Masson, P. (2017). Chronic kidney disease. The lancet, 389(10075), 1238-1252.

Wright, M., Southcott, E., MacLaughlin, H., & Wineberg, S. (2019). Clinical practice guideline on undernutrition in chronic kidney disease. BMC nephrology, 20, 1-10.

Zhang, W. R., & Parikh, C. R. (2019). Biomarkers of acute and chronic kidney disease. Annual review of physiology, 81(1), 309-333.

Zoccali, C., Mallamaci, F., Adamczak, M., de Oliveira, R. B., Massy, Z. A., Sarafidis, P., Agarwal, R., Mark, P. B., Kotanko, P., & Ferro, C. J. (2023). Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association. Cardiovascular Research, 119(11), 2017-2032.

Downloads

Published

2025-10-22

How to Cite

Alobaisi, Y. S., Anwar, F., Dabour, K., Almatham, K., Alshahrani, S., Alzahrani, K. A., Ahmed, Y. A., & Alobaysi, M. M. (2025). Indication of laboratory parameters for kidney diseases at King Fahad Medical City, Riyadh, Saudi Arabia. American Journal of Medical Science and Innovation, 4(2), 78–88. https://doi.org/10.54536/ajmsi.v4i2.5340